We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.00 | 35.10 | 35.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 206.76 | 189.86M |
TIDMAPH
RNS Number : 3767M
Alliance Pharma PLC
21 September 2021
For immediate release 21 September 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Interim results for the six months ended 30 June 2021
Strong growth from Consumer Healthcare brands and integration of Amberen complete
Full year outlook in line with market expectations
Alliance Pharma plc (AIM: APH), the international healthcare group, announces its interim results for the six months ended 30 June 2021 (the "Period").
HIGHLIGHTS
-- The Group traded strongly in the Period with an excellent performance from Kelo-cote(TM), an uplift in revenue from Prescription Medicines and a significant contribution from recently acquired Amberen(TM)
-- See-through revenue in total up 24% (+28% on a constant currency basis ("CCY")) to GBP80.9m; like-for-like ("LFL") see-through revenue, which excludes Amberen, up 9% (+12% CCY); statutory revenue up 27% to GBP78.6m (H1 2020 GBP61.7m)
o Strong performance from Consumer Healthcare brands, with see-through revenue up 30% overall (+35% CCY)
-- Kelo-cote revenue up 54% (+62% CCY)
-- LFL Consumer Healthcare revenue up 8% (+12% CCY)
o Prescription Medicines revenue up 12% (+12% CCY)
-- Underlying gross margin up 4.7 % to 63.8% of see-through revenue (H1 2020: 59.1%), reflecting favourable changes in product mix; statutory gross margin up 3.1% to 65.6% (H1 2020: 62.5%)
-- Underlying profit before tax up 24% to GBP20.1m (H1 2020: GBP16.3m); reported profit before tax GBP16.5m (H1 2020: GBP0.6m)
-- Free cash flow GBP6.5m (H1 2020: GBP10.5m), reflecting the expected reversal of favourable working capital movements in Q4 2020 and the timing of sales within the Period
-- Leverage reduced to 2.21 times from 2.43 times at December 2020 and expected to fall below 2.0 times by the end of the year
-- Amberen integration complete and trading in line with management expectations -- Interim dividend payment of 0.563p, up 5% (interim dividend 2020: 0.536p)
REVENUE SUMMARY
Unaudited six months ended H1 2021 H1 2020 Growth CCY growth 30 June GBPm GBPm Kelo-cote 21.9 14.2 +54% +62% ------------------------------------ -------- -------- ------- ----------- Amberen 9.5 - - - ------------------------------------ -------- -------- ------- ----------- Nizoral* 9.0 9.8 -8% -7% ------------------------------------ -------- -------- ------- ----------- Other consumer brands 16.4 19.8 -17% ------------------------------------ -------- -------- ------- ----------- Consumer Healthcare 56.8 43.8 +30% +35% ------------------------------------ -------- -------- ------- ----------- Prescription Medicines 24.1 21.5 +12% +12% ------------------------------------ -------- -------- ------- ----------- See-through revenue* 80.9 65.3 +24% +28% ------------------------------------ -------- -------- ------- ----------- LFL Consumer Healthcare revenue, excluding Amberen 47.3 43.8 +8% +12% ------------------------------------ -------- -------- ------- ----------- LFL see-through revenue, excluding Amberen 71.4 65.3 +9% +12% ------------------------------------ -------- -------- ------- -----------
FINANCIAL SUMMARY
Unaudited six months ended H1 2021 H1 2020 Growth 30 June GBPm GBPm See-through Revenue* 80.9 65.3 +24% ----------------------------------- -------- ---------- ------- Statutory Revenue 78.6 61.7 +27% ----------------------------------- -------- ---------- ------- Gross profit 51.6 38.6 +34% ----------------------------------- -------- ---------- ------- Underlying EBITDA* 22.8 18.1 +26% ----------------------------------- -------- ---------- ------- Underlying profit before taxation 20.1 16.3 +24% ----------------------------------- -------- ---------- ------- Reported profit before taxation 16.5 0.6 ----------------------------------- -------- ---------- ------- Underlying basic earnings per share 2.99p 2.45p +22% ----------------------------------- -------- ---------- ------- Reported basic earnings per share 1.54p (0.33)p ----------------------------------- -------- ---------- ------- Free cash flow* 6.5 10.5 -38% ----------------------------------- -------- ---------- ------- Leverage 2.21x 2.43x (31 Dec) ----------------------------------- -------- ---------- ------- Net debt* 105.4 109.4 (31 Dec) ----------------------------------- -------- ---------- ------- Interim dividend per share 0.563p 0.536p +5% ----------------------------------- -------- ---------- -------
* The performance of the Group is assessed using Alternative Performance Measures ("APMs"), which are measures that are not defined under IFRS, but are used by management to monitor ongoing business performance against both shorter term budgets and forecasts and against the Group's longer term strategic plans. APMs are defined in note 17.
Specifically, see-through revenue includes sales from Nizoral(TM) as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in each of the Asia-Pacific territories transfer from J&J to Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15.
Commenting on the interim results, Peter Butterfield, Chief Executive Officer of Alliance, said :
"The Group has delivered another strong performance in the first half of 2021, with the uplift in revenue from our enlarged Consumer Healthcare business flowing through to pre-tax profits. We expect this core part of our business to continue to grow strongly during the remainder of the year, led by Kelo-cote and Amberen.
"We were very pleased with the first half performance from Amberen, which was acquired in December 2020 and has traded in line with our expectations. With the integration of the brand into our US-based operations now complete, we can focus on maximising the value of this key brand.
"Trading for the remainder of the financial year remains in line with market expectations. We expect the combination of positive trading and working capital movements to result in Group leverage falling below 2.0x by the end of the year."
WEBCAST & ANALYST Q&A CALL
A pre-recorded presentation of the half year results, by Peter Butterfield, Chief Executive Officer, and Andrew Franklin, Chief Financial Officer, will be available at 7.05am today at the investor section of Alliance's website, https://www.alliancepharmaceuticals.com/investors/
and at https://webcasting.buchanan.uk.com/broadcast/6127786112f0cb436ea67ef8
A Q&A call for analysts will be held at 10.00am today; analysts who require joining details should contact Buchanan at alliancepharma@buchanan.uk.com .
For further information:
Alliance Pharma plc + 44 (0)1249 466966 Peter Butterfield, Chief Executive Officer Andrew Franklin, Chief Financial Officer www.alliancepharma.co.uk Buchanan + 44 (0)20 7466 5000 Mark Court / Sophie Wills / Hannah Ratcliff Numis Securities Limited + 44 (0)20 7260 1000 Nominated Adviser: Freddie Barnfield / Duncan Monteith Corporate Broking: James Black Investec Bank plc + 44 (0) 20 7597 5970 Corporate Finance: Daniel Adams Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
More information on Alliance can be found on our website: www.alliancepharmaceuticals.com
CHIEF EXECUTIVE'S STATEMENT
Trading performance
Overview
The Group delivered another strong performance in the Period, with see-through revenue up 24% to GBP80.9m (H1 2020: GBP65.3m), despite the impact of currency headwinds and continuing lockdowns, particularly in the APAC region; on a constant currency basis, revenue was up 28%. Like-for-like revenue, excluding Amberen, which was acquired by the Group at the end of 2020, was up 9% (up 12% on a constant currency basis).
Gross profit increased by 34% to GBP51.6m (H1 2020: GBP38.6m), the increase outstripping revenue growth due to favourable changes in product mix. This was balanced by an increase in operational costs, primarily reflecting the inclusion of the Amberen cost base. Coupled with small increases in depreciation charges and financing costs, underlying profit before tax increased 24% to GBP20.1m (H1 2020: GBP16.3m), with the profit before tax margin being maintained at 25%.
Consumer Healthcare performance
Overall, see-through revenue across our Consumer Healthcare brands increased by 30% in the Period to GBP56.8m (H1 2020: GBP43.8m) and by 35% on a constant currency basis. On a like-for-like basis, excluding Amberen, see-through revenue increased by 8% (12% CCY).
Our leading brands generally performed well during the Period, with a particularly strong performance from Kelo-cote and an encouraging start by Amberen since acquisition in December 2020.
Kelo-cote - scar prevention and treatment
Kelo-cote growth accelerated strongly in the Period, with sales up 54% to GBP21.9m (H1 2020: GBP14.2m), notwithstanding the impact of adverse currency movements. On a constant currency basis, sales were up 62% due to continued strong demand from China, reflected both in the growth of domestic sales and in significant growth in cross-border e-commerce ("CBEC") sales.
Kelo-cote is very well established in China, with high brand awareness and usage. The growth in domestic and CBEC sales reflects the increasing trend for consumers in China and elsewhere to buy more of the brand, and healthcare products generally, online. This trend has been accelerated by the global pandemic.
In recognition of the success of CBEC in facilitating export sales from the EU to consumers in China, and the significant opportunity China offers as a growth driver for this key brand, we have recently entered into a new CBEC distribution agreement for Kelo-cote, which gets us closer to the customer and gives us further control of our distribution chain. We expect this to further accelerate top-line growth in this key market in the medium term.
Performance across the rest of APAC, South America and EMEA was more mixed, primarily due to the continuing impacts of the global pandemic, and the timing of distributor orders. Sales to a number of APAC countries, including Hong Kong and South Korea, benefited from a post-COVID-19 recovery, whilst distributor order phasing benefited sales to South America notwithstanding the resurgence of the pandemic negatively impacting in-market demand. In EMEA, strong performances from a number of European territories including France (domestic and export sales) and the UK were partially offset by distributor order phasing adversely affecting sales to the Middle East and Africa.
Amberen - vitamin mineral supplement for the relief of menopause symptoms (US)
Amberen made an encouraging start during its first period of trading under the Group's ownership, generating sales of GBP9.5m, up 10% on a constant currency basis versus sales for the last six months under its previous ownership and in line with management's expectations.
Growth from the Perimenopause product, launched in June 2020, has been particularly encouraging with the product now having a 7% market share, double that at acquisition. Just 12 months after launch, it is now the fifth largest SKU in the category by value.
Full year sales expectations continue to be weighted towards the second half, reflecting an increased focus on media investment and online marketing.
Nizoral - medicated anti-dandruff shampoo
Nizoral see-through sales were 8% lower than for the prior period, at GBP9.0m (H1 2020: GBP9.8m), 7% lower on a constant currency basis, due to a combination of distributor order phasing, manufacturing delays, and the ongoing impacts of COVID-19 on demand, particularly in India, and on the processing of regulatory approvals in Vietnam and the Philippines.
We are now starting to roll out our strategic brand plan for Nizoral, with consumer activation underway in South Korea, Australia, Taiwan and the Philippines as part of a growth strategy centred around consumer and healthcare professional activation, e-commerce, and innovation and development.
Excellence in execution will be key to realising the growth opportunities for the brand across the 14 culturally diverse markets in the APAC region in which it is sold, and particularly in China, which is currently the brand's largest market and one that represents a significant growth opportunity for Nizoral.
Other Consumer Healthcare brands
Performance across our other Consumer Healthcare brands was mixed, particularly for those products sold principally through international distributors . We saw a strong performance from MacuShield (eye health supplement), with first half sales up 54% on those for the prior period at GBP4.4m (H1 2020: GBP2.8m), reflecting the recovery of UK retail sales adversely affected in the first half of 2020 by COVID-19 and the normalisation of distributor stocking post Brexit. However, other brands, including Vamousse, Aloclair and Oxyplastine, continued to be adversely affected by COVID-19 and the knock-on impact of the pandemic on distributor stocking and order phasing.
Vamousse ( prevention and treatment of head lice ) sales were down 28% (-22% CCY) versus the prior period at GBP2.3m (H1 2020: GBP3.2m), reflecting ongoing trading challenges due to COVID-19, with the incidence of head lice, and hence the demand for treatment and prevention products, continuing to be suppressed by school closures, particularly in the US, the product's primary market. That said, the head lice category in the US is now starting to show month-on-month growth and Vamousse continues to track ahead of category performance, having gained 1.6 percentage points of market share over the 52 weeks to 19 June 2021.
Aloclair ( treatment for mouth ulcers ) saw sales fall by 40% in the Period to GBP2.7m (H1 2020: GBP4.6m), as distributors continued to respond to changes in local trading conditions as a result of COVID-19. As lockdowns ease, we would expect demand to normalise .
Sales of Oxyplastine (treatment for skin irritations, including nappy rash) fell by 58% to GBP0.9m in the Period (H1 2020: GBP2.2m), due to import restrictions and COVID-19 related impacts on distributor sales to Algeria, historically the brand's largest market. Both Oxyplastine and Aloclair tend to generate relatively low margins, thereby limiting the impact of the reduction in revenues at the gross margin level.
Prescription Medicines performance
Sales from our Prescription Medicines portfolio increased by 12% in the Period to GBP24.1m (H1 2020: GBP21.5m), reflecting a partial return to the delivery of routine treatments and normalisation of daily life compared with the early stages of the pandemic.
We continue to actively manage this part of our portfolio, periodically discontinuing or disposing of smaller products that deliver very low sales and margins. However, the cash generation from these assets remains good and, coupled with their limited requirement for promotional investment, they will continue to play an important part in our overall product portfolio.
Regional performance
EMEA
Across the EMEA region as a whole, first half sales were up 11% versus those for the prior period at GBP49.9m (H1 2020: GBP44.8m).
This was primarily due to the uplift in Prescription Medicines sales, with this region accounting for 95% of all Prescription Medicines sales in the Period, coupled with a significant uplift in CBEC sales of Kelo-cote from the EU to China, and the uplift in MacuShield sales, which originate primarily in EMEA (the largest market is the UK).
APAC
See-through sales across the APAC region as a whole were up 6% versus the prior period at GBP17.9m (H1 2020: GBP16.9m), notwithstanding the continuing impacts of local lockdowns across much of this region.
APAC is primarily a Consumer Healthcare region, with consumer products accounting for approximately 95% of total see-through sales in the region. The dominant brands are Kelo-cote and Nizoral (which is only sold by Alliance in APAC), which collectively account for almost 90% of the region's see-through sales.
The uplift in sales reflects growth in Kelo-cote sales, both in China and across the wider APAC region, coupled with a slight decline in Nizoral sales, primarily due to distributor order phasing.
AMER
Sales in the AMER region increased by GBP9.4m to GBP13.0m (H1 2020: GBP3.6m), reflecting the acquisition of Amberen, which contributed GBP9.5m to sales in the Period. On a like-for-like basis, sales were marginally down on the prior period at GBP3.5m, with the decline in Vamousse sales in the US being largely offset by increased sales of Kelo-cote to South America, and increased Aloclair sales. This region now accounts for just under a quarter of our Consumer Healthcare revenue.
Current trading and outlook
The second half of the year has started well, and we remain confident in our ability to meet market expectations in terms of revenue, underlying profits and net debt.
We now have a significant new opportunity to drive further growth for Kelo-cote through our CBEC business and to start to realise the growth potential in Nizoral through 2022 and beyond.
Amberen has got off to an encouraging start, and we remain confident in our ability to leverage the growth potential in this key brand going forward.
With the integration of Amberen now complete, we continue to look for opportunities to selectively add to our Consumer Healthcare portfolio, leveraging the platform we have built across EMEA, APAC and, more recently, the US.
Operational developments
Group infrastructure, systems and processes
Our new Innovation & Development process is now fully up and running, increasing our ability to extend the reach of our larger consumer brands through brand extensions (new formulations, targeting related sub-sectors, or new presentations) in addition to refreshing existing products to maintain consumer appeal.
We have also started to roll out our new Digital Excellence training programme to our global marketing teams, to ensure our staff have the necessary skills and knowledge in this area to drive sustainable long- term value.
Our ERP system has now gone live and is already starting to deliver business benefits through the standardisation of processes, with the high level of preparation undertaken pre-go-live ensuring a virtually seamless changeover. Work continues on refining some of the reporting requirements and rolling the system out to a few remaining smaller entities.
We have recently completed further substantial upgrading and refurbishment works at our UK headquarters, improving the building's environmental credentials whilst also reconfiguring space to better accommodate post-pandemic working arrangements. We have recently secured new, larger offices in Cary, North Carolina, to accommodate our growing US team.
Amberen integration
Operationally, integration of Amberen into the business is now complete. A number of new hires have recently been made in the US to strengthen our operating capabilities to better support Amberen and Vamousse and also to enhance our ability to scale up as and when a suitable US acquisition opportunity arises.
Ways of working
At the start of July, we rolled out a new hybrid working model for our employees around the globe to enable them to balance home working with a return to the office. We will continue to refine this during the remainder of the year, as our understanding of what works best, both for our employees and for the business, increases.
Building a sustainable business
We have continued to work on developing our sustainable business strategy in the Period, under the direction of the ESG Board Committee, revisiting our materiality assessment, carrying out an external ESG gap analysis and engaging with many of our key investors in order to develop a Balanced Scorecard for the business and inform future areas of focus. More detail can be found in the accompanying results presentation.
Board changes
As previously announced, Kristof Neirynck, a highly experienced consumer brands executive, will be joining the Group on 1 December 2021 as an independent Non-Executive Director. Kristof brings almost 20 years of international consumer brand experience including complex omni-channel business models, direct-to-consumer strategies and CBEC sales into China to the Group. His experience will be invaluable as we look to further develop and grow our business, in particular our CBEC activities, over the coming years.
Peter Butterfield
Chief Executive Officer
21 September 2021
FINANCIAL REVIEW
Summary underlying income statement
Unaudited six months ended 30 June H1 2021 H1 2020 Growth GBPm GBPm See-through Revenue* 80.9 65.3 +24% ------------------------------------- -------- -------- ------- Statutory Revenue 78.6 61.7 +27% ------------------------------------- -------- -------- ------- Gross profit 51.6 38.6 +34% ------------------------------------- -------- -------- ------- Operating expenses (including IFRS 2 share options charge) (28.8) (20.5) +41% ------------------------------------- -------- -------- ------- Underlying EBITDA* 22.8 18.1 +26% ------------------------------------- -------- -------- ------- Depreciation (1.1) (0.8) +32% ------------------------------------- -------- -------- ------- Underlying EBIT* 21.7 17.2 +26% ------------------------------------- -------- -------- ------- Finance costs (1.6) (1.0) +58% ------------------------------------- -------- -------- ------- Underlying profit before taxation 20.1 16.3 +24% ------------------------------------- -------- -------- ------- Reported profit before taxation 16.5 0.6 ------------------------------------- -------- -------- ------- Underlying basic earnings per share 2.99p 2.45p +22% ------------------------------------- -------- -------- ------- Reported basic earnings per share 1.54p (0.33)p ------------------------------------- -------- -------- ------- Interim dividend per share 0.563p 0.536p +5% ------------------------------------- -------- -------- -------
* The performance of the Group is assessed using Alternative Performance Measures ("APMs"), which are measures that are not defined under IFRS, but are used by management to monitor ongoing business performance against both shorter-term budgets and forecasts and against the Group's longer-term strategic plans. APMs are defined in note 17.
Specifically, see-through revenue includes sales from Nizoral(TM) as if they had been invoiced by Alliance. Under the terms of the transitional services agreement with Johnson & Johnson (J&J), Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15.
Underlying profitability metrics are presented as we believe this provides investors with useful information about the performance of the business. For 2021, underlying results exclude the amortisation of intangible assets; for 2020, underlying results exclude the amortisation and impairment of intangible assets. Further detail can be found in note 6.
The Group delivered a strong financial performance in the Period, with see-through revenue increasing 24% to GBP80.9m (H1 2020: GBP65.3m) and statutory revenue increasing 27% to GBP78.6m (H1 2020: GBP61.7m). Like-for-like revenue excluding Amberen increased by 9%. Whilst operating expenses increased, due mainly to the inclusion of the Amberen cost base coupled with small increases in depreciation and finance costs, underlying profit before tax as a percentage of sales was maintained with underlying profit before tax increasing 24% to GBP20.1m (H1 2020: GBP16.3m).
Group revenue was adversely impacted by exchange rate movements, principally the strengthening of Sterling against the US Dollar, which depressed see-through revenue by approximately GBP2.4m. On a constant currency basis, see-through revenue increased 28% overall and 12% on a like-for-like basis.
Gross profit increased by a larger percentage than sales at 34% to GBP51.6m (H1 2020: GBP38.6m), with gross margin increasing from 59.1% to 63.8% of see-through revenue, reflecting favourable changes in product mix. Gross margin relative to statutory revenue was 65.6% (H1 2020: 62.5%).
Operating costs (defined as underlying administration and marketing expenses, excluding depreciation charges) were up by GBP7.4m versus the prior Period at GBP27.3m (H1 2020: GBP19.9m) due primarily to the inclusion of the Amberen cost base, coupled with the resumption of discretionary spend deferred or cancelled in H1 2020 in response to the global pandemic and increased levels of investment in the business more generally. As a result, operating costs as a percentage of sales increased 3.4% to 33.9% of see-through sales (H1 2020: 30.5%).
The IFRS 2 share options charge for the Period was GBP1.5m, up GBP0.9m versus that for the prior period (H1 2020: GBP0.6m).
Net of the increase in operating costs and the share options charge, underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 26% in the Period to GBP22.8m (H1 2020: GBP18.1m), whilst underlying operating profit increased by a similar percentage to GBP21.7m (H1 2020: GBP17.2m) and reported operating profit increased by GBP16.5m to GBP18.1m (H1 2020: GBP1.6m).
Depreciation
Depreciation charges for the Period were GBP1.1m, up GBP0.3m on the prior period (H1 2020: GBP0.8m).
Finance costs
Finance costs were up by GBP0.6m compared with the prior period at GBP1.6m (H1 2020: GBP1.0m), GBP0.3m of which related to an increase in borrowing costs, reflecting the higher level of borrowings following the Amberen acquisition and the remainder relating primarily to lower net gains on currency movements in the Period of GBP0.2m (H1 2020: GBP0.6m).
The average interest charge on gross debt during the Period (including non-utilisation fees) was 2.04% (H1 2020: 2.78%).
Non-underlying items
Non-underlying items in the Period comprise amortisation charges for Prescription Medicines and certain other brand assets; for the prior period, non-underlying items comprise amortisation charges and impairment charges.
Reconciliation of underlying to reported profit before tax
Unaudited six months ended 30 June H1 2021 H1 2020 GBPm GBPm Underlying profit before taxation 20.1 16.3 --------------------------------------- -------- -------- Non-underlying items: --------------------------------------- -------- -------- Amortisation of intangible assets (3.6) (3.6) --------------------------------------- -------- -------- Impairment of intangible assets and goodwill - (12.1) --------------------------------------- -------- -------- Total (3.6) (15.6) --------------------------------------- -------- -------- Reported profit before taxation 16.5 0.6 --------------------------------------- -------- --------
Taxation
The underlying tax charge for the Period was GBP4.1m (H1 2020: GBP3.3m), which equates to an effective tax rate of 20.5% (H1 2020: 20.0%). The total tax charge for the Period was GBP8.3m (H1 2020: GBP2.4m) and includes a GBP5.1m charge following the decision to increase the UK tax rate from 19% to 25% (this charge relates primarily to an increase in the deferred tax balances on intangible assets) partially offset by a tax credit on non-qualifying amortisation of GBP0.9m.
Earnings per share
Underlying basic earnings per share, the measure used by the Board in assessing earnings performance, was 2.99p, an increase of 22% on the prior period (H1 2020: 2.45p), reflecting the increase in the Group's underlying profit after tax coupled with a modest increase in the number of shares in issue.
Reported basic earnings per share increased by 1.87p to 1.54p (H1 2020: (0.33p)) due to the impact of non-underlying items on reported earnings in the Period versus the prior period.
Dividend
The Board is pleased to announce that it is declaring an interim dividend payment of 0.563p per share for 2021, an increase of 5% on the 0.536p interim dividend for 2020. The Board will continue to assess the level of future cash distributions having regard to overall business performance and future outlook.
The interim dividend for 2021 will be paid on 7 January 2022, to shareholders on the register on 24 December 2021.
Balance sheet
Intangible assets reduced by GBP5.7m in the Period to GBP407.2m (31 December 2020: GBP412.9m), reflecting amortisation charges of GBP3.6m together with GBP1.9m due to exchange rate movements and a GBP0.2m true-up for working capital relating to the Amberen acquisition.
Further detail is provided in note 10.
Working capital
Net working capital at 30 June 2021 was GBP27.7m, an increase of GBP8.4m on that at the start of the Period (31 December 2020: GBP19.3m), reflecting an expected increase in receivables as a result of sales timings.
Inventories, net of provisions, amounted to GBP23.2m at 30 June 2021 (31 December 2020: GBP22.9m), the minimal movement reflecting our decision to maintain the higher levels of finished goods inventory, raw materials and componentry built up during 2020 in order to mitigate against any disruption to our supply chain following the UK's departure from the EU.
As noted above, receivables increased by GBP8.5m, reflecting the timing of sales, with second quarter 2021 sales being weighted towards the end of the quarter, versus fourth quarter 2020 sales, which were weighted towards the start of the quarter. We expect receivables to reduce by the end of the year, based on expected sales timings. There was minimal movement in payables, which increased by GBP0.4m.
Cash flow and net debt
Free cash flow for the Period was GBP6.5m (H1 2020: GBP10.5m), the reduction reflecting the expected reversal of the favourable working capital movements in the fourth quarter of 2020 and the timing of sales within the Period. Net debt reduced by GBP4.0m to GBP105.4m as at 30 June 2021 and Group leverage reduced to 2.21 times at the end of June (31 December 2020: 2.43 times). We continue to expect leverage to fall below 2.0 times by the end of the year.
Treasury and capital management
The Group's operations are financed by retained earnings and bank borrowings, with additional equity being raised on a periodic basis to part-fund larger acquisitions. Borrowings are denominated in Sterling, Euro and US Dollars.
Group risk management policy is to hedge up to 75% of estimated future foreign currency EBITDA exposure, for up to the next 18 months at any point in time. The Group uses forward foreign exchange contracts to implement this policy which are generally designated as cash flow hedges.
The Group benefits from a GBP165m Revolving Credit Facility (RCF) and a GBP50m Accordion Facility, expiring in July 2024. This facility provides flexibility for the Group to pursue its acquisition strategy over the next couple of years to complement future organic growth. GBP32m of this RCF remained unutilised as at 30 June 2021.
We apply the cash generated from our trading operations in reinvesting in our current portfolio of brands, with investment being primarily targeted at our larger Consumer Healthcare brands, acquiring new Consumer Healthcare brands, to complement our existing portfolio and leverage our operating platform, paying down debt and paying dividends to our shareholders.
Andrew Franklin
Chief Financial Officer
21 September 2021
UNAUDITED CONSOLIDATED INCOME STATEMENT
For the six months ended 30 June 2021
Unaudited Unaudited Six months ended Six months ended 30 June 2021 30 June 2020 ==================================== ===================================== Underlying Non-Underlying Underlying Non-Underlying GBP000s GBP000s GBP000s GBP000s Note (Note Total (Note Total 6) GBP000s 6) GBP000s ============================== ========== ============== ======== ========== ============== ========= Revenue 4 78,629 - 78,629 61,708 - 61,708 Cost of sales (27,029) - (27,029) (23,117) - (23,117) ============================= ========== ============== ======== ========== ============== ========= Gross profit 51,600 - 51,600 38,591 - 38,591 ============================= ========== ============== ======== ========== ============== ========= Operating expenses Administration and marketing expenses (28,469) - (28,469) (20,747) - (20,747) Amortisation of intangible assets 6 - (3,584) (3,584) - (3,577) (3,577) Impairment of goodwill and intangible assets 6 - - - - (12,057) (12,057) Share-based employee remuneration (1,476) - (1,476) (595) - (595) Operating profit/(loss) 21,655 (3,584) 18,071 17,249 (15,634) 1,615 ============================= ========== ============== ======== ========== ============== ========= Finance costs Interest payable and similar charges 5 (1,773) - (1,773) (1,558) - (1,558) ============================= ========== ============== ======== ========== ============== ========= Finance income 5 217 - 217 572 - 572 ============================= ========== ============== ======== ========== ============== ========= (1,556) - (1,556) (986) - (986) ============================= ========== ============== ======== ========== ============== ========= Profit/(loss) before taxation 20,099 (3,584) 16,515 16,263 (15,634) 629 ============================== ========== ============== ======== ========== ============== ========= Taxation 7 (4,126) (4,149) (8,275) (3,253) 856 (2,397) ============================= ========== ============== ======== ========== ============== ========= Profit/(loss) for the period attributable to equity shareholders 15,973 (7,733) 8,240 13,010 (14,778) (1,768) ============================== ========== ============== ======== ========== ============== ========= Earnings per share Basic (pence) 9 2.99 1.54 2.45 (0.33) Diluted (pence) 9 2.94 1.52 2.42 (0.33) ============================= ========== ============== ======== ========== ============== =========
Unaudited Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2021
Unaudited Unaudited Six months Six months ended ended 30 June 2021 30 June 2020 GBP000s GBP000s =========================================== ============= ============= (Loss)/profit for the period 8,240 (1,768) Other comprehensive income Items that may be reclassified to profit or loss: Interest rate swaps - cash flow hedge (net of deferred tax) - (10) Forward exchange forward contracts - cash flow hedge (net of deferred tax) 303 (762) Foreign exchange translation differences (net of deferred tax) (1,790) 2,863 =========================================== ============= ============= Total comprehensive income for the period 6,753 323 =========================================== ============= =============
Unaudited Consolidated Balance Sheet
As at 30 June 2021
Audited Unaudited 31 December 30 June 2021 2020 Note GBP000s GBP000s ================================= ==== ============= ============ Assets Non-current assets Goodwill and intangible assets 10 407,168 412,872 Property, plant and equipment 11 19,344 15,921 Deferred tax asset 2,064 2,139 Other non-current assets 612 682 ================================= ==== ============= ============ 429,188 431,614 Current assets Inventories 23,223 22,917 Trade and other receivables 12 33,562 25,114 Derivative financial instruments 597 310 Cash and cash equivalents 27,390 28,898 ================================= ==== ============= ============ 84,772 77,239 ================================= ==== ============= ============ Total assets 513,960 508,853 ================================= ==== ============= ============ Equity Ordinary share capital 5,353 5,329 Share premium account 150,964 150,645 Share option reserve 9,146 8,426 Other reserve (329) (329) Cash flow hedging reserve 542 239 Translation reserve (2,845) (1,055) Retained earnings 117,338 117,703 ================================= ==== ============= ============ Total equity 280,169 280,958 ================================= ==== ============= ============ Liabilities Non-current liabilities Loans and borrowings 15 132,768 138,238 Other liabilities 14 3,083 3,200 Deferred tax liability 59,429 56,181 ================================= ==== ============= ============ 195,280 197,709 ================================= ==== ============= ============ Current liabilities Corporation tax 3,642 1,435 Trade and other payables 13 29,122 28,736 Derivative financial instruments - 15 Dividend payable 5,747 - ================================= ==== ============= ============ 38,511 30,186 ================================= ==== ============= ============ Total liabilities 233,791 227,895 ================================= ==== ============= ============ Total equity and liabilities 513,960 508,853 ================================= ==== ============= ============
Unaudited Consolidated Statement of Cash Flows
For the six months ended 30 June 2021
Unaudited Unaudited Six months Six months ended ended 30 June 30 June 2021 2020 Note GBP000s GBP000s ========================================== ==== ============= =========== Operating activities Profit for the period before tax 16,515 629 Interest payable and similar charges 5 1,773 1,558 Interest income 5 (21) (10) Foreign exchange gain 5 (196) (562) Depreciation of property, plant and equipment 11 1,100 831 Amortisation and impairment of intangible assets 10 3,584 15,634 Loss on disposal of intangibles - 309 Share-based employee remuneration 1,476 595 Change in inventories (306) (2,674) Change in trade and other receivables (8,879) 1,798 Change in trade and other payables (553) (1,687) ========================================== ==== ============= =========== Cash generated from operations 14,493 16,421 ========================================== ==== ============= =========== Tax paid (2,236) (1,964) ========================================== ==== ============= =========== Cash flows from operating activities 12,257 14,457 ========================================== ==== ============= =========== Investing activities Acquisitions (consideration adjustment) 183 - Interest received 5 21 10 Purchase of property, plant and equipment 11 (4,284) (1,949) Proceeds from the disposal of intangibles 500 385 ========================================== ==== ============= =========== Net cash used in investing activities (3,580) (1,554) ========================================== ==== ============= =========== Financing activities Interest paid and similar charges (1,481) (1,974) Loan issue costs 15 - (330) Proceeds from exercise of share options 343 712 Capital lease payments (436) (426) Dividend paid 8 (2,858) (2,837) Repayment of borrowings 15 (5,362) (5,930) ========================================== ==== ============= =========== Net cash used in financing activities (9,794) (10,785) ========================================== ==== ============= =========== Net movement in cash and cash equivalents (1,117) 2,118 ========================================== ==== ============= =========== Cash and cash equivalents at beginning of period 28,898 17,830 ========================================== ==== ============= =========== Effects of exchange rate movements (391) 576 ========================================== ==== ============= =========== Cash and cash equivalents at end of period 27,390 20,524 ========================================== ==== ============= ===========
Unaudited Consolidated Statement of Changes in Equity
For the six months ended 30 June 2021
Cash Ordinary Share Share flow Share Premium Option Other Hedging Translation Retained Total Capital account reserve reserve reserve reserve earnings Equity GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s ==================================== ======== ======== ======== ======== ============ ========= ======== Balance 1 January 2021 (audited) 5,329 150,645 8,426 (329) 239 (1,055) 117,703 280,958 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Issue of shares 24 319 - - - - - 343 Dividend paid/payable - - - - - - (8,605) (8,605) Share options charge (including deferred
tax) - - 720 - - - - 720 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Transactions with owners 24 319 720 - - - (8,605) (7,542) ============================= ===== ======== ======== ======== ======== ============ ========= ======== Profit for the period - - - - - 8,240 8,240 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Other comprehensive income ============================================== ======== ======== ======== ============ ========= ======== Foreign exchange forward contracts - cash flow hedge (net of deferred tax) - - - - 303 - - 303 Foreign exchange translation differences - - - - - (1,790) - (1,790) ============================= ===== ======== ======== ======== ======== ============ ========= ======== Total comprehensive income for the period - - - - 303 (1,790) 8,240 6,753 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Balance 30 June 2021 (unaudited) 5,353 150,964 9,146 (329) 542 (2,845) 117,338 280,169 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Cash Ordinary Share Share flow Share Premium Option Other Hedging Translation Retained Total Capital account reserve reserve reserve reserve earnings Equity GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s GBP000s ==================================== ======== ======== ======== ======== ============ ========= ======== Balance 1 January 2020 (audited) 5,294 149,036 7,208 (329) 462 (4) 112,513 274,180 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Issue of shares 17 696 - - - - - 713 Dividend paid - - - - - - (2,837) (2,837) Share options charge (including deferred tax) - - 510 - - - - 510 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Transactions with owners 17 696 510 - - - (2,837) (1,614) ============================= ===== ======== ======== ======== ======== ============ ========= ======== Loss for the period - - - - - - (1,768) (1,768) ============================= ===== ======== ======== ======== ======== ============ ========= ======== Other comprehensive income ============================================== ======== ======== ======== ============ ========= ======== Interest rate swaps - cash flow hedge (net of deferred tax) - - - - (10) - - (10) Foreign exchange forward contracts - cash flow hedge (net of deferred tax) - - - - (762) - - (762) Foreign exchange translation differences - - - - - 2,863 - 2,863 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Total comprehensive income for the period - - - - (772) 2,863 (1,768) 323 ============================= ===== ======== ======== ======== ======== ============ ========= ======== Balance 30 June 2020 (unaudited) 5,311 149,732 7,718 (329) (310) 2,859 107,908 272,889 ============================= ===== ======== ======== ======== ======== ============ ========= ========
Notes to the Half Year Report
For the six months ended 30 June 2021
1. General information
Alliance Pharma plc ('the Company') and its subsidiaries (together 'the Group') acquire, market, and distribute consumer healthcare products and prescription medicines. The Company is a public limited company, limited by shares, registered, incorporated, and domiciled in England and Wales in the UK. The address of its registered office is Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB.
The Company is listed on the London Stock Exchange, Alternative Investment Market ('AIM').
The information in these financial statements does not constitute statutory accounts as defined in section 434 of the Companies Act 2006 and is unaudited. These financial statements have been prepared in accordance with the AIM rules, and IAS 34 has not been adopted. A copy of the Group's statutory accounts for the year ended 31 December 2020, prepared in accordance with international accounting standards in conformity with the requirements of the Companies Act 2006 ('Adopted IFRS'), has been delivered to the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain statements under section 498(2) or section 498(3) of the Companies Act 2006.
These consolidated financial statements for the six-month period ended 30 June 2021 have been approved for issue by the Board of Directors on 17 September 2021.
2. Going concern
The Group has access to a GBP165m fully Revolving Credit Facility ('RCF'), with an additional GBP50m accordion facility, expiring in July 2024.
The RCF is drawn in short to medium-term tranches of debt which are repayable within 12 months of draw-down. These tranches of debt can be rolled over provided certain conditions are met, including covenant compliance. The Group considers that it is highly unlikely it would be unable to exercise its right to roll over the debt. This due to mitigating actions it could take to maintain compliance with these conditions, including future covenant requirements, even in downside scenarios.
The Directors have prepared cashflow forecasts for a period of 12 months from the date of approval of these financial statements (the forecast period), that include current estimates of the continued impact of COVID-19 on the Group's trading position. These indicate that the Group will have sufficient funds to meet its liabilities as they fall due, and will continue to comply with its loan covenants, throughout the forecast period.
Consequently, the Directors are confident that the Group will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and have therefore determined it is appropriate to adopt the going concern basis in preparing the financial statements.
3. Accounting policies
Judgements and estimates
The Group segregates its portfolio of assets into two areas: Consumer Healthcare brands and Prescription Medicines.
For the majority of Consumer Healthcare brand assets, indefinite useful lives are considered to be appropriate. This is due to the expected long-term growth profile of the Consumer Healthcare business and the enduring nature of the brands, which are supported by continuing marketing spend.
For Prescription Medicines brand assets, finite useful lives of up to 20 years have been adopted from 1 January 2020. The determination of this lifespan takes into account all relevant factors for each individual asset, including typical pharmaceutical asset life cycles and the potential development of alternative treatments over time.
The carrying value of the Prescription Medicines and certain other brand assets is amortised to the profit and loss account over their useful lives.
The Group conducts regular impairment reviews for all intangible brand assets. The results of recent reviews are detailed in note 6.
Non-underlying items
All amortisation and impairment charges for intangible assets are included as non-underlying items. The revaluation of deferred tax balances following substantial tax legislation changes are also included as non-underlying items. The Directors believe that this classification of underlying and non-underlying items, when considered together with total statutory results, provides investors, analysts and other stakeholders with helpful complementary information to understand better the financial performance and position of the Group from period to period, and allows the Group's performance to be more easily compared against the majority of its peer companies. These measures are also used by management for planning and reporting purposes. They may not be directly comparable with similarly described measures used by other companies.
Other accounting policies
The remaining accounting policies applied in these interim financial statements are the same as those published by the Group in the 31 December 2020 Annual Report. The Annual Report is available on the Group's website: www.alliancepharmaceuticals.com.
4. Revenue
Unaudited Unaudited Six months Six months ended 30 ended 30 June 2021 June 2020 Revenue information by brand GBP000s GBP000s =========================================== =========== =========== Consumer healthcare brands: Kelo-cote 21,871 14,181 Amberen 9,491 - Nizoral* 6,738 6,209 MacuShield 4,367 2,837 Vamousse 2,332 3,217 Aloclair 2,722 4,553 Other Consumer healthcare brands 7,057 9,195 =========================================== =========== =========== Total Revenue - Consumer healthcare brands 54,578 40,192 =========================================== =========== =========== Prescription medicines: Hydromol 3,384 3,300 Flamma Franchise 3,575 2,897 Forceval 2,675 2,322 Other Prescription medicines 14,417 12,997 =========================================== =========== =========== Total Revenue - Prescription medicines 24,051 21,516 =========================================== =========== =========== Total Revenue 78,629 61,708 =========================================== =========== =========== Unaudited Six months Unaudited ended Six months 30 June ended 30 2021 June 2020 Revenue information by geography GBP000s GBP000s ====================================== =========== =========== Europe, Middle East and Africa (EMEA) 49,940 44,791 Asia Pacific and China (APAC) 15,653 13,299 Americas (AMER) 13,036 3,618 ====================================== =========== =========== Total Revenue 78,629 61,708 ====================================== =========== ===========
* Nizoral is shown on a net profit basis in statutory revenue. Nizoral revenue presented on a see-through income statement basis is included as an alternative performance measure in note 17.
5. Finance costs
Unaudited Unaudited Six months Six months ended 30 ended 30 June 2021 June 2020 GBP000s GBP000s ===================================== =========== =========== On loans and overdrafts (1,408) (1,139) Amortised finance issue costs (318) (267) Net fair value losses on derivatives - (109) Interest on lease liabilities (47) (43) ===================================== =========== =========== Interest payable and similar charges (1,773) (1,558) ===================================== =========== =========== Interest income 21 10 Net exchange gain 196 562 ===================================== =========== =========== Finance income 217 572 ===================================== =========== =========== Net finance costs (1,556) (986) ===================================== =========== ===========
6. Non-underlying items
The Group presents a number of non-IFRS measures which exclude the impact of significant non-underlying items. This is to allow investors to understand the underlying performance of the Group, and can exclude items such as: amortisation and impairment of intangibles; gains or losses on disposal; remeasurement and accounting for the passage of time in respect of contingent considerations; and the revaluation of deferred tax balances following substantial tax legislation changes.
This assessment requires judgement to be applied by the Directors as to which transactions are non-underlying and whether this classification enhances the understanding of the users of the financial statements.
Unaudited Unaudited Six months Six months ended 30 ended 30 June 2021 June 2020 GBP000s GBP000s ============================================== =========== =========== Amortisation of intangible assets 3,584 3,577 Impairment of goodwill and intangible assets - 12,057 ============================================== =========== =========== Total non-underlying items before taxation 3,584 15,634 ============================================== =========== =========== Taxation on amortisation and impairment items (903) (2,298) Impact of UK tax rate change from 17% to 19% - 1,442 Impact of UK tax rate change from 19% to 25% 5,052 - ============================================== =========== =========== Non-underlying taxation 4,149 (856) ============================================== =========== =========== Total non-underlying items after taxation 7,733 14,778 ============================================== =========== ===========
Amortisation of intangible assets
As disclosed in note 3, finite useful lives of up to 20 years have been adopted from 1 January 2020 for Prescription Medicines and certain other brand assets. The carrying value of the Prescription Medicines and certain other brand assets is amortised to the profit and loss account over their useful lives.
Impairment of goodwill and intangible assets
The Group conducts regular impairment reviews for all intangible assets and no impairment charges arose as a result of the review carried out in the current period.
The review carried out in the period to 30 June 2020, together with the change in useful life assumption for Prescription Medicine assets, resulted in impairment losses as the carrying value of certain cash-generating units exceeded estimated recoverable amounts. Recoverable amounts are the greater of value in use and fair value less costs to sell over the assets' useful lives.
The key Prescription Medicines assets impacted were:
Haemopressin and Optiflo intangible asset impaired by GBP5.3m.
Nu-seals intangible asset impaired by GBP3.6m.
Goodwill and other intangible assets were also impaired by GBP3.2m.
Impact of UK tax rate change from 17% to 19%
The taxation charge includes the impact on deferred tax of the increase in the main rate of UK corporation tax from 17% to 19%, following the abandonment of the proposed reduction to 17% in the March 2020 Budget.
Impact of UK tax rate change from 19% to 25%
In the Budget on 3 March 2021, a further change to UK corporation tax rates was announced, increasing the main rate of corporation tax from 19% to 25% with effect from 1 April 2023. The impact on deferred tax of this further rate increase is included in these financial statements as a non-underlying item.
7. Taxation
Analysis of charge for the period is as follows:
Unaudited Unaudited Six months ended 30 Six months ended 30 June 2021 June 2020 ============= ==================================== ==================================== Non-Underlying Non-Underlying GBP000s GBP000s Underlying (Note Total Underlying (Note Total GBP000s 6) GBP000s GBP000s 6) GBP000s ============== ========== ============== ======== ========== ============== ======== Corporation tax 4,126 - 4,126 2,439 - 2,439 Deferred tax - 4,149 4,149 814 (856) (42) ============== ========== ============== ======== ========== ============== ======== Taxation 4,126 4,149 8,275 3,253 (856) 2,397 ============== ========== ============== ======== ========== ============== ========
The difference between the total tax charge and the amount calculated by applying the standard rate of UK corporation tax to profit before tax is as follows:
Unaudited Unaudited Six months Six months ended ended 30 30 June June 2021 2020 GBP000s GBP000s ======================= ============ ============ Profit before taxation 16,515 629 ======================= ============ ============ Profit before taxation multiplied by standard rate of corporation tax in the United Kingdom at 19% (2019: 19%) 3,138 120 Effects of: Non-deductible items and adjustments 988 163 Non-qualifying amortisation and impairment (903) 672 UK rate change impact (note 6) 5,052 1,442 =============================================== ===== ===== Total tax charge 8,275 2,397 =============================================== ===== =====
8. Dividends
The Board has declared an interim dividend payment of 0.563p per share for the 2021 financial year. This will be paid to shareholders in January 2022.
Six months ended 30 June 2021 Pence/share GBP000s ============================================= ============ ========== Amounts recognised as distributions to shareholders in 2021 =========================================================== ========== Interim dividend for the 2020 financial year 0.536 2,858 Final dividend for the 2020 financial year 1.074 5,747 ============================================= ============ ========== 8,605 ============================================= ============ ==========
The interim dividend for 2020 was paid on 7 January 2021. The final dividend for 2020 was paid on 8 July 2021.
Six months ended 30 June 2020 Pence/share GBP000s ==================================================== ============ ========== Amounts recognised as distributions to shareholders in 2020 Interim dividend for the 2019 financial year 0.536 2,837 ==================================================== ============ ==========
The interim dividend for 2019 was paid on 10 January 2020.
9. Earnings per share ('EPS')
Basic EPS is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of Ordinary Shares outstanding during the period. For diluted EPS, the weighted average number of Ordinary Shares in issue is adjusted to assume conversion of all dilutive potential Ordinary Shares.
A reconciliation of the weighted average number of Ordinary Shares used in the measures is given below:
Weighted average number of shares 000s ================ ========================= Six months Six months ended ended 30 June 30 June 2021 2020 ================ ============= ========== For basic EPS 534,189 530,303 Share options 8,667 6,875 ================ ============= ========== For diluted EPS 542,855 537,178 ================ ============= ========== Six months Six months to to 30 June 30 June 2021 2020 GBP000s GBP000s ========================================== ============= ========== Earnings for basic and diluted EPS 8,240 (1,768) Non-underlying items (note 6) 7,733 14,778 ========================================== ============= ========== Earnings for underlying basic and diluted EPS 15,973 13,010 ========================================== ============= ========== The resulting EPS measures are: Six months Six months to to 30 June 30 June 2021 2020 Pence Pence ======================= ============== =========== Basic EPS 1.54 (0.33) ======================= ============== =========== Diluted EPS 1.52 (0.33) ======================= ============== =========== Underlying basic EPS 2.99 2.45 ======================= ============== =========== Underlying diluted EPS 2.94 2.42 ======================= ============== ===========
10. Goodwill and intangible assets
Consumer Prescription Healthcare Medicines brands brands Goodwill and distribution and distribution GBP000s rights rights Total GBP000s GBP000s GBP000s ========================================= ========== ================= ================= ======== Cost At 1 January 2021 (audited) 32,404 258,203 152,890 443,497 Acquisitions (consideration adjustment*) (183) - - (183) Exchange adjustments (201) (952) (784) (1,937) ========================================= ========== ================= ================= ======== At 30 June 2021 (unaudited) 32,020 257,251 152,106 441,377 ========================================= ========== ================= ================= ======== Amortisation and impairment At 1 January 2021 (audited) 1,144 6,459 23,022 30,625 Amortisation for the period (note 6) - 103 3,481 3,584 ========================================= ========== ================= ================= ======== At 30 June 2021 (unaudited) 1,144 6,562 26,503 34,209 ========================================= ========== ================= ================= ======== Net book amount At 30 June 2021 (unaudited) 30,876 250,689 125,603 407,168 ========================================= ========== ================= ================= ======== At 1 January 2021 (audited) 31,260 251,744 129,868 412,872 ========================================= ========== ================= ================= ========
* The consideration adjustment relates to a working capital adjustment in relation to the Biogix acquisition.
11. Property, plant and equipment
Computer Fixtures, Right-of-use software fitting Plant lease and equipment and equipment & machinery assets Total The Group GBP000s GBP000s GBP000s GBP000s GBP000s ============================ ============== ============== ============ ============ ========= Cost At 1 January 2021 (audited) 13,048 2,511 32 6,739 22,330 Additions 3,289 933 62 275 4,559 Effect of movements in exchange rates - - (5) - (5) ============================ ============== ============== ============ ============ ========= At 30 June 2021 (unaudited) 16,337 3,444 89 7,014 26,884 ============================ ============== ============== ============ ============ ========= Depreciation At 1 January 2021 (audited) 1,620 1,408 8 3,373 6,409 Provided in the period 414 245 34 407 1,100 Effect of movements in exchange rates 23 - (15) 23 31 ============================ ============== ============== ============ ============ ========= At 30 June 2021 (unaudited) 2,057 1,653 27 3,803 7,540 ============================ ============== ============== ============ ============ ========= Net book amount
At 30 June 2021 (unaudited) 14,280 1,791 62 3,211 19,344 ============================ ============== ============== ============ ============ ========= At 1 January 2021 (audited) 11,428 1,103 24 3,366 15,921 ============================ ============== ============== ============ ============ =========
12. Trade and other receivables
Unaudited Audited 30 June 31 December 2021 2020 GBP000s GBP000s =============================== ========== ============= Trade receivables 29,147 19,834 Other receivables 1,375 1,544 Prepayments and accrued income 3,040 3,736 =============================== ========== ============= 33,562 25,114 =============================== ========== =============
13. Trade and other payables
Unaudited Audited 30 June 31 December 2021 2020 GBP000s GBP000s ====================================== ========== ============= Trade payables 10,168 11,275 Other taxes and social security costs 2,574 2,440 Accruals and deferred income 14,077 13,639 Other payables 1,190 418 Lease liabilities 1,113 964 ====================================== ========== ============= 29,122 28,736 ====================================== ========== =============
14. Other non-current liabilities
Unaudited Audited 30 June 31 December 2021 2020 GBP000s GBP000s ============================== ========== ============= Lease liabilities 2,610 2,731 Other non-current liabilities 473 469 ============================== ========== ============= 3,083 3,200 ============================== ========== =============
15. Loans and borrowings
The Group has access to a GBP165m fully Revolving Credit Facility ('RCF'), with an additional GBP50m accordion facility, expiring in July 2024.
The bank facility is secured by a fixed and floating charge over the Company's and Group's assets registered with Companies House.
The Group also has access to an overdraft facility of GBP4.0m.
Movements in borrowings are analysed as follows:
GBP000s ========================================= ======= At 1 January 2021 (audited) 138,328 Repayment of borrowings (5,362) Amortisation of prepaid arrangement fees 305 Exchange movements* (503) ========================================= ======= At 30 June 2020 (unaudited) 132,768 ========================================= =======
* Exchange movements on loans and borrowings are reported in other comprehensive income and accumulated in the translation reserve.
The carrying amount of the group's borrowings are denominated in the following currencies:
Unaudited Audited 30 June 31 December 2020 2020 GBP000s GBP000s ================= ========== ============= GBP 100,817 105,317 USD 25,138 25,322 EUR 8,099 9,281 Loan issue costs (1,286) (1,592) ================= ========== ============= 132,768 138,238 ================= ========== =============
16. Contingent liabilities
On 23 May 2019, the UK's Competition and Markets Authority ('CMA') issued a Statement of Objection alleging anti-competitive agreements against the Group and certain other pharmaceutical companies in relation to the sale of prescription prochlorperazine. Prochlorperazine is one of the Group's smaller products and had peak sales in 2015 of GBP1.9m and sales of GBP0.3m in 2020.
The Group confirms that it has had no involvement in the pricing or distribution of prochlorperazine since 2013, when it was outlicensed by the Group. Prior to 2013, prochlorperazine was marketed directly by the Group.
The Group has reviewed the CMA Statement of Objection in detail and is working with the CMA to resolve its alleged objections.
The Group's assessment as at the date of this report, based on currently available information, is that there are no matters for which a provision is required (31 December 2020: GBPnil). However, given the inherent uncertainties involved in assessing the outcomes of such matters there can be no assurance regarding the outcome of any ongoing inspections/investigations and the position could change over time.
17. Alternative performance measures
The performance of the Group is assessed using Alternative Performance Measures ('APMs'). The Group's results are presented both before and after non-underlying items. Adjusted profitability measures are presented excluding non-underlying items as we believe this provides both management and investors with useful additional information about the Group's performance and aids a more effective comparison of the Group's trading performance from one period to the next and with similar businesses.
In addition, the Group's results are described using certain other measures that are not defined under IFRS and are therefore considered to be APMs. These measures are used by management to monitor ongoing business performance against both shorter-term budgets and forecasts but also against the Group's longer-term strategic plans.
APMs used to explain and monitor Group performance are:
Reconciliation Measure Definition to GAAP measure ================= ===================================================== ================ Underlying Earnings before interest, tax and non-underlying Note A below EBIT and items ('EBIT'), then depreciation, amortisation EBITDA and underlying impairment ('EBITDA'). Calculated by taking profit before tax and financing costs, excluding non-underlying items and adding back depreciation and amortisation. ================= ===================================================== ================ Free cash Free cash flow is defined as cash generated Note B below flow from operations less cash payments made for financing costs, capital expenditure and tax. ================= ===================================================== ================ Net debt Net debt is defined as the Group's gross Note C below bank debt position net of finance issue costs and cash. ================= ===================================================== ================ See-through Under the terms of the transitional services Note D below income statement agreement with J&J, Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance. The net product margin is recognised as part of statutory revenue. The see-through income statement recognises the underlying sales and cost of sales which give rise to the net product margin, as management consider this to be a more meaningful representation of the underlying performance of the business, and to reflect the way in which it is managed. ================= ===================================================== ================
A. Underlying EBIT and EBITDA
Unaudited Unaudited Six months Six months ended ended 30 June 30 June 2021 2020 Reconciliation of Underlying EBIT and EBITDA GBP000s GBP000s ============================================= =========== =========== Profit before tax 16,515 629 Non-underlying items (note 6) 3,584 15,634 Net finance costs (note 5) 1,556 986 ============================================= =========== =========== Underlying EBIT 21,655 17,249 Depreciation (note 11) 1,100 831 Underlying EBITDA 22,755 18,080 ============================================= =========== ===========
B. Free cash flow
Unaudited Unaudited Six months Six months ended ended 30 June 30 June 2021 2020 Reconciliation of free cash flow GBP000s GBP000s ================================= =========== =========== Cash generated from operations 14,493 16,421 Financing costs (1,481) (1,974) Capital expenditure (4,284) (1,949) Tax paid (2,236) (1,964) ================================= =========== =========== Free cash flow 6,492 10,534 ================================= =========== ===========
C. Net debt
Unaudited Audited 30 June 31 December 2021 2020 Reconciliation of net debt GBP000s GBP000s =================================== ========= ============= Loans and borrowings - non-current (132,768) (138,238) Cash and cash equivalents 27,390 28,898 =================================== ========= ============= Net debt (105,378) (109,430) =================================== ========= =============
D. See-through income statement
Unaudited Unaudited Six months Six months ended ended 30 June 30 June 2021 2021 statutory See-through see-through values adjustment values GBP000s GBP000s GBP000s ==================== =========== =========== ============ Revenue 78,629 2,224 80,853 Cost of sales (27,029) (2,224) (29,253) ==================== =========== =========== ============ Gross profit 51,600 - 51,600 ==================== =========== =========== ============ Gross profit margin 65.6% - 63.8% ==================== =========== =========== ============
There is no impact from the see-through adjustment on income statement lines below gross profit.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR FLFVDAIIIFIL
(END) Dow Jones Newswires
September 21, 2021 02:00 ET (06:00 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions